Equities

Exicure Inc

Exicure Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.41
  • Today's Change-0.19 / -7.31%
  • Shares traded4.00
  • 1 Year change-31.20%
  • Beta1.2868
Data delayed at least 15 minutes, as of Oct 09 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company is into exploring strategic alternatives to maximize stockholder value. It is engaging in a broader exploration of strategic alternatives. This effort involves exploring growth through transactions with potential partners that see opportunity in joining an existing, publicly traded organization. The Company is exploring transactions in industries unrelated to its historical operations. It does not generate any revenues. It wholly owned subsidiary is Exicure Operating Company that holds all material assets and conducts all business activities and operations of the Company.

  • Revenue in USD (TTM)500.00k
  • Net income in USD-8.17m
  • Incorporated2017
  • Employees5.00
  • Location
    Exicure Inc2430 N. HALSTED ST.CHICAGO 60614United StatesUSA
  • Phone+1 (847) 673-1700
  • Fax+1 (847) 556-6411
  • Websitehttps://www.exicuretx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Notable Labs Ltd313.00k-16.74m3.72m16.00--0.5175--11.88-2.47-2.470.0460.74390.0176----19,562.50-93.89-52.02-120.26-62.0937.7060.19-5,346.97-3,636.93----0.0405---52.89-11.9365.13---50.69--
Enveric Biosciences Inc0.00-10.59m3.73m7.00--0.6102-----3.67-3.670.000.68620.00----0.00-133.67-104.94-206.10-156.88-------243.54----0.00------7.14------
Theriva Biologics Inc0.00-22.27m3.75m21.00--1.43-----1.25-1.250.001.230.00----0.00-41.30-36.95-48.49-40.16------------0.0056------8.37--95.91--
CTT Pharmaceutical Holdings Inc0.00-1.67m3.75m0.00--2.02-----0.0822-0.08220.000.03460.00-------317.2813.49-448.83304.48------------0.00-------3,454.52------
Azitra Inc408.20k-9.96m3.81m10.00--0.2779--9.33-12.12-12.120.11511.800.0595--1.8340,820.00-145.30---194.72-------2,440.46------0.0191--141.55--6.02------
Synaptogenix Inc0.00-3.45m3.88m5.00--0.1969-----3.89-3.890.0014.990.00----0.00-5.54-40.33-6.89-43.36------------0.00-------142.17---3.21--
Ainos Inc65.12k-15.41m3.88m46.00--0.1719--59.55-3.17-3.170.01262.800.00190.781413.861,415.65-44.29-36.36-49.13-58.33-316.6236.82-23,664.28-813.631.45-55.500.4016---96.539.461.69--66.44--
CNS Pharmaceuticals Inc0.00-15.97m3.94m3.00---------134.04-134.040.00-2.970.00----0.00-358.12-132.47---185.75---------------------23.42------
Palisade Bio Inc0.00-14.17m3.99m9.00--0.3274-----20.07-20.070.0010.300.00----0.00-90.97-132.36-109.07-165.45-------27,892.32---972.730.0339-----0.781413.74--18.53--
Lixte Biotechnology Holdings Inc0.00-4.03m4.00m3.00---------1.83-1.830.000.99860.00----0.00-139.98-104.18-163.33-111.05-----------563.880.00------19.41------
Galera Therapeutics Inc0.00-29.11m4.03m7.00---------0.5892-0.58920.00-2.540.00----0.00-90.03-83.69-119.01-97.54-----------14.3411.60------5.05---29.84--
Exicure Inc500.00k-8.17m4.17m5.00--2.59--8.34-4.72-4.720.28890.93230.0354----83,333.34-57.87-41.52-69.90-55.78-----1,634.40-290.95----0.3827---100.00---555.07------
Qualigen Therapeutics Inc0.00-9.27m4.32m4.00---------1.66-1.750.00-0.4450.00----0.00-134.64-----------------9.64--------10.22------
Vaccinex Inc356.00k-17.76m4.68m37.00------13.14-24.59-24.590.3183-1.810.1306--0.67429,621.62-651.39-262.29---------4,987.92-4,257.17---52.60----107.27-4.67-2.20---22.20--
Weed Inc0.0057.30k4.69m2.0074.51623.9854.26--0.00050.00050.000.000060.00----0.006.00-385.93---822.37-----------46.080.944------97.93---59.13--
Data as of Oct 09 2024. Currency figures normalised to Exicure Inc's reporting currency: US Dollar USD

Institutional shareholders

3.05%Per cent of shares held by top holders
HolderShares% Held
Geode Capital Management LLCas of 30 Jun 202456.52k0.65%
Northwestern University (Investment Management)as of 30 Jun 202452.15k0.60%
The Vanguard Group, Inc.as of 31 Mar 202440.09k0.46%
Millennium Management LLCas of 31 Mar 202434.80k0.40%
Two Sigma Securities LLCas of 31 Mar 202422.70k0.26%
Citadel Securities LLCas of 31 Mar 202418.16k0.21%
Renaissance Technologies LLCas of 30 Jun 202414.90k0.17%
Bank of America, NA (Private Banking)as of 31 Mar 202412.80k0.15%
Tower Research Capital LLCas of 31 Mar 20247.03k0.08%
BlackRock Fund Advisorsas of 31 Mar 20245.11k0.06%
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.